Literature DB >> 20144313

The case for personalized medicine.

Edward Abrahams1, Mike Silver.   

Abstract

Personalized medicine may be considered an extension of traditional approaches to understanding and treating disease, but with greater precision. Physicians may now use a patient's genetic variation or expression profile as well as protein and metabolic markers to guide the selection of certain drugs or treatments. In many cases, the information provided by molecular markers predicts susceptibility to conditions. The added precision introduces the possibility of a more preventive, effective approach to clinical care and reductions in the duration and cost of clinical trials. Here, we make the case, through real-world examples, that personalized medicine is delivering significant value to individuals, to industry, and to the health care system overall and that it will continue to grow in importance if we can lift the barriers that impede its adoption and build incentives to encourage its practice. Copyright 2009 Diabetes Technology Society.

Entities:  

Mesh:

Year:  2009        PMID: 20144313      PMCID: PMC2769975          DOI: 10.1177/193229680900300411

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  12 in total

Review 1.  Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review.

Authors:  K A Phillips; D L Veenstra; E Oren; J K Lee; W Sadee
Journal:  JAMA       Date:  2001-11-14       Impact factor: 56.272

2.  Special report: genotyping for cytochrome P450 polymorphisms to determine drug-metabolizer status.

Authors: 
Journal:  Technol Eval Cent Assess Program Exec Summ       Date:  2004-12

Review 3.  Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force.

Authors:  Heidi D Nelson; Laurie Hoyt Huffman; Rongwei Fu; Emily L Harris
Journal:  Ann Intern Med       Date:  2005-09-06       Impact factor: 25.391

4.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.

Authors:  J P Struewing; P Hartge; S Wacholder; S M Baker; M Berlin; M McAdams; M M Timmerman; L C Brody; M A Tucker
Journal:  N Engl J Med       Date:  1997-05-15       Impact factor: 91.245

5.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

Authors:  M A Cobleigh; C L Vogel; D Tripathy; N J Robert; S Scholl; L Fehrenbacher; J M Wolter; V Paton; S Shak; G Lieberman; D J Slamon
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

6.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

7.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Authors:  Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

Review 8.  Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies.

Authors:  Chuenjid Kongkaew; Peter R Noyce; Darren M Ashcroft
Journal:  Ann Pharmacother       Date:  2008-07-01       Impact factor: 3.154

9.  Long-term compliance with lipid-lowering medication after genetic screening for familial hypercholesterolemia.

Authors:  Marina A W Umans-Eckenhausen; Joep C Defesche; Marjel J van Dam; John J P Kastelein
Journal:  Arch Intern Med       Date:  2003-01-13

10.  The HapMap Resource is Providing New Insights into Ourselves and its Application to Pharmacogenomics.

Authors:  Wei Zhang; Mark J Ratain; M Eileen Dolan
Journal:  Bioinform Biol Insights       Date:  2008-02-01
View more
  7 in total

Review 1.  New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis.

Authors:  Qiang Ding; Tracy Luckhardt; Louise Hecker; Yong Zhou; Gang Liu; Veena B Antony; Joao deAndrade; Victor J Thannickal
Journal:  Drugs       Date:  2011-05-28       Impact factor: 9.546

2.  The personalized medicine for diabetes meeting summary report.

Authors:  David C Klonoff
Journal:  J Diabetes Sci Technol       Date:  2009-07-01

Review 3.  Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

Authors:  Mariusz Panczyk
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

Review 4.  Molecular Probes, Chemosensors, and Nanosensors for Optical Detection of Biorelevant Molecules and Ions in Aqueous Media and Biofluids.

Authors:  Joana Krämer; Rui Kang; Laura M Grimm; Luisa De Cola; Pierre Picchetti; Frank Biedermann
Journal:  Chem Rev       Date:  2022-01-07       Impact factor: 60.622

5.  Guidance for pharmacogenomic biomarker testing in labels of FDA-approved drugs.

Authors:  Alexandre Vivot; Isabelle Boutron; Philippe Ravaud; Raphaël Porcher
Journal:  Genet Med       Date:  2014-12-18       Impact factor: 8.822

6.  Bayesian group sequential enrichment designs based on adaptive regression of response and survival time on baseline biomarkers.

Authors:  Yeonhee Park; Suyu Liu; Peter F Thall; Ying Yuan
Journal:  Biometrics       Date:  2021-01-27       Impact factor: 1.701

Review 7.  Data Integration Challenges for Machine Learning in Precision Medicine.

Authors:  Mireya Martínez-García; Enrique Hernández-Lemus
Journal:  Front Med (Lausanne)       Date:  2022-01-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.